The forecast for the import of antisera and other blood fractions into China shows a steady upward trend, starting from $7.385 billion in 2024 and reaching $8.5361 billion by 2028. Compared to previous years, this signifies continued growth from 2023, however, specific figures from 2023 are required for deeper year-on-year comparisons. The compound annual growth rate (CAGR) over these five years reflects a steady increase, indicative of China's expanding healthcare sector and rising demand for medical supplies.
Looking ahead, key trends to monitor include:
- The impact of domestic production capabilities on import levels.
- Regulatory changes affecting the import of biologics.
- Technological advancements and innovation in blood fraction derivatives.
- China's healthcare policy interventions which may influence import dynamics.
